Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Magenta Therapeutics, Inc. MGTA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
26/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Magenta Therapeutics, Inc. (MGTA) is a Biotechnology company in the Healthcare sector, currently trading at $0.70. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $2M, -67.3%/yr average growth. Net income is $162M (loss), growing at -39.6%/yr. Net profit margin is -7973.3% (negative). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1M against $493M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 13.32 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $531M.

Analyst outlook: 4 / 10 analysts rate MGTA as buy (40%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 11/100 (Fail), Future 20/100 (Fail), Income 10/100 (Fail).

MGTA SharesGrow Score Overview

31/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 11/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MGTA

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
MGTA: -67.3%/yr revenue is, -39.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet MGTA: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 13.32 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
11/100
MGTA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 11/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 4 / 10 analysts rate MGTA as buy (40%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
MGTA: Net profit margin is -7973.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.321-1.81
Volume375.91K
Avg Volume (30D)247.98K
Market Cap$42.44M
Beta (1Y)2.11
Share Statistics
IPO Date2018-06-21
Employees67
CEOStephen F. Mahoney MBA
Financial Highlights & Ratios
Revenue (TTM)$2.04M
EBITDA$-177.93M
Net Income$-162.34M
Operating Income$-177.93M
Total Cash$404.3M
Total Debt$1.39M
Net Debt$-49.7M
Total Assets$530.92M
Price / Sales (P/S)20.85
Analyst Forecast
Rating ConsensusHold
Analysts Covering10
Buy 40% Hold 60% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS55910K1088

Price Chart

Track all markets on TradingView
MGTA
Magenta Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.32 52WK RANGE 1.81

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.82
-0.72%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.56
+0.44%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.81
+1.26%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.64
-5.04%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 TIL
TIL
Instil Bio, Inc.
$8.89
+5.33%
 NXTC
NXTC
NextCure, Inc.
$12.02
-5.87%
 NLTX
NLTX
Neoleukin Therapeutics, Inc.
$3.49
+1.45%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message